| [1] |
FLOREANI A, OKAZAKI K, UCHIDA K, et al. IgG4-related disease: Changing epidemiology and new thoughts on a multisystem disease[J]. J Transl Autoimmun, 2020, 4: 100074. DOI: 10.1016/j.jtauto.2020.100074.
|
| [2] |
OBIORAH I E, HENAO V A, OZDEMIRLI M. The clinicopathologic spectrum of IgG4-related disease[J]. Balkan Med J, 2018, 35(4): 292-300. doi: 10.4274/balkanmedj.2018.0809
|
| [3] |
BENNETT A E, FENSKE N A, RODRIGUEZ-WAITKUS P, et al. IgG4-related skin disease may have distinct systemic manifestations: A systematic review[J]. Int J Dermatol, 2016, 55(11): 1184-1195. doi: 10.1111/ijd.13369
|
| [4] |
张文, 董凌莉, 朱剑, 等. IgG-4相关性疾病诊治中国专家共识[J]. 中华内科杂志, 2021, 60(3): 192-206. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGD202109013.htm
ZHANG W, DONG L L, ZHU J, et al. Chinese expert consensus on the diagnosis and treatment of IgG4-related diseases[J]. Chinese Journal of Internal Medicine, 2021, 60(3): 192-206. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGD202109013.htm
|
| [5] |
WALLACE Z S, PERUGINO C, MATZA M, et al. Immunoglobulin G4-related disease[J]. Clin Chest Med, 2019, 40(3): 583-597. doi: 10.1016/j.ccm.2019.05.005
|
| [6] |
TAKAYAMA R, UENO T, SAEKI H. Immunoglobulin G4-related disease and its skin manifestations[J]. J Dermatol, 2017, 44(3): 288-296. doi: 10.1111/1346-8138.13723
|
| [7] |
SHENOY A, MOHANDAS N, GOTTLIEB A. Cutaneous and systemic IgG4-related disease: A review for dermatologists[J]. Dermatol Online J, 2019, 25(6): 13030. DOI: 10.5070/D3256044441.
|
| [8] |
ISHIMOTO U, KINOSHITA A, KOIKE K, et al. Punctate purpura complicated with Immunoglobulin G4-related disease[J]. Intern Med, 2021, 60(6): 867-872. doi: 10.2169/internalmedicine.5138-20
|
| [9] |
刘佳玮, 刘薇, 马东来. IgG4相关性疾病的皮肤表现[J]. 临床皮肤科杂志, 2017, 46(10): 733-735. https://www.cnki.com.cn/Article/CJFDTOTAL-LCPF201710019.htm
LIU J W, LIU W, MA D L. Skin manifestation of IgG4-related disease[J]. Journal of Clinical Dermatology, 2017, 46(10): 733-735. https://www.cnki.com.cn/Article/CJFDTOTAL-LCPF201710019.htm
|
| [10] |
WALLACE Z S, NADEN R P, CHARI S, et al. The 2019 American college of Rheumatology/European League against rheumatism classification criteria for IgG4-related disease[J]. Arthritis Rheumatol, 2020, 72(1): 7-19. doi: 10.1002/art.41120
|
| [11] |
WANG K K, WANG Z F, ZENG Q Z, et al. Clinical characteristics of IgG4-related retroperitoneal fibrosis versus idiopathic retroperitoneal fibrosis[J]. PLoS One, 2021, 16(2): e245601. DOI: 10.1371/journal.pone.0245601.
|
| [12] |
TANG J G, CAI S Z, YE C, et al. Biomarkers in IgG4-related disease: A systematic review[J]. Semin Arthritis Rheum, 2020, 50(2): 354-359. doi: 10.1016/j.semarthrit.2019.06.018
|
| [13] |
HARA A, WATANABE T, MINAGA K, et al. Biomarkers in autoimmune pancreatitis and immunoglobulin G4-related disease[J]. World J Gastroenterol, 2021, 27(19): 2257-2269. doi: 10.3748/wjg.v27.i19.2257
|
| [14] |
MATSUMOTO H, FUJITA Y, MATSUOKA N, et al. Serum checkpoint molecules in patients with IgG4-related disease (IgG4-RD)[J]. Arthritis Res Ther, 2021, 23(1): 148. doi: 10.1186/s13075-021-02527-6
|
| [15] |
ZHANG P P, GONG Y Y, LIU Z, et al. Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4-related diseases: A prospective clinical trial[J]. Int J Rheum Dis, 2019, 22(8): 1479-1488. doi: 10.1111/1756-185X.13633
|
Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com
Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2
Supported by:
Beijing Renhe Information Technology Co., Ltd.
DownLoad: